Biotechnology Deals Will Surpass 2015’s Record

Deal volume in the Biotechnology sector is poised to surpass last year’s record-setting 160 transactions. With two weeks left in 2016, deal volume has reached 159 transactions. The activity in this sector shows no signs of abating, and will probably carry through the first half of 2017, at least.

Big Pharma Pays Big for Biotech Pipelines

The pharmaceutical industry has largely given up on in-house research and development, saying that the R&D timeline is too costly, long and uncertain to fund with shareholders’ money. The industry has gone from bolt-on acquisitions of smaller companies with marketed products to battling it out for clinical-stage drug candidates. What’s surprised some industry observers is […]

Pfizer Buys Medivation and More

Forget those early- to mid-stage clinical candidates. Pfizer Inc. (NYSE: PFE) jumped the line with its $13.5 billion deal for oncology drug maker Medivation Inc. (NASDAQ: MDVN). The target’s primary product is XTANDI® (enzalutamide), an androgen receptor inhibitor, the leading novel hormone therapy for the treatment of prostate cancer. Pfizer will pay $81.50 per share in […]

Pharma M&A Is all about Options

The days of mega-mergers in the pharmaceutical sector aren’t necessarily over, but those deals will be fewer and farther between, going forward. Nearly 60 deals have been announced in 2016 through the middle of May, and just 17 have an entire company as the target. The largest, so far, is Shire‘s (NASDAQ: SHPG) $32 billion […]

AbbVie Gets Ahead of the Bad News Curve

On March 11, Sanofi (NYSE: SNY)  and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) announced that an experimental rheumatoid arthritis therapy (salrilumab) helped patients more than AbbVie Inc.’s (NYSE: ABBV) Humira in a late-stage trial. But AbbVie already had a new deal in place, a collaboration with Boehringer Ingelheim, that was announced on March 7. Under terms of the agreement, AbbVie […]

Hanmi Pharmaceutical Deals with Sanofi, Janssen

Korean pharmaceutical company Hanmi Pharmaceutical Co., Ltd. popped up on the healthcare M&A radar last week with two collaboration announcements. First was an agreement with French drug maker Sanofi (NYSE: SNY) to grant the worldwide license to a yet-to-be developed portfolio of experimental, long-acting diabetes treatments. Sanofi paid an upfront fee of €400 million ($434,820,000) and is […]